Rimantadine


Concise Prescribing Info
Indications/Uses
Prophylaxis and treatment of influenza A.
Dosage/Direction for Use
Adult : PO 100 mg twice daily.
Dosage Details
Oral
Influenza A
Adult: 100 mg twice daily.
Elderly: ≥65 yr: 100 mg once daily

Oral
Prophylaxis of influenza A
Adult: 100 mg twice daily.
Child: 1-9 yr: 5 mg/kg (max: 150 mg) once daily; ≥10 yr and <40 kg: 5 mg/kg/day in 2 divided doses; ≥10 yr and ≥40 kg : 100 mg twice daily.
Elderly: 100 mg daily.
Renal Impairment
CrClDosage
≤10 mL/min100 mg daily
Hepatic Impairment
Severe hepatic impairment: 100 mg daily.
Contraindications
Hypersensitivity to drugs of the adamantane class, such as rimantadine and amantadine.
Special Precautions
Renal or hepatic impairment. Elderly. Monitor for GI and CNS adverse reactions. May increase risk of seizures in patients with a history of epilepsy, discontinue treatment if seizure occurs. History of eczema or psychosis. Pregnancy.
Adverse Reactions
Nausea, vomiting, abdominal pain, diarrhoea, dyspepsia, xerostomia, taste alteration, anorexia, headache, insomnia, impaired concentration, nervousness, dizziness, asthenia, ataxia, bronchospasm, depression, skin rash and tinnitus.
Potentially Fatal: Cardiac failure and heart block.
Drug Interactions
Rimantadine should not be used for at least 2 wk after the admin of live influenza virus vaccines. Live influenza vaccines can only be given at least 48 hr after stopping rimantadine.
Action
Description: Rimantadine inhibits viral replication via interference of the influenza A viral M2 protein. The M2 protein is a membrane protein that acts as an ion channel; it is involved in several aspects of viral replication. By interfering with the ion channel function of M2 protein, rimantadine possibly inhibits the uncoating of the virus and prevents viral maturation in selected strains of influenza A. WHO has noted in an alert dated 5 May 2009 that tests on viral samples obtained from patients in Mexico and United States affected by the current new influenza A H1N1 strain are resistant to adamantanes, including rimantadine.
Pharmacokinetics:
Absorption: Readily absorbed from the GI tract: peak concentrations after 6 hr.
Distribution: Protein binding: About 40% (mainly albumin)
Metabolism: Largely metabolised in the liver; metabolised to at least 3 hydroxylated metabolites.
Excretion: <25% of the drug is excreted unchanged in urine; elimination half-life: 25-38 hr; clearance unaffected by haemodialysis.
Storage
Store at 15-30°C.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Rimantadine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in